These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26808479)

  • 21. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against influenza virus isolates in the 2011-2012 season in Japan.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2014 Feb; 20(2):77-80. PubMed ID: 24560563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of the MDCK cell selected neuraminidase D151G mutation on the drug susceptibility assessment of influenza A(H3N2) viruses.
    Mishin VP; Sleeman K; Levine M; Carney PJ; Stevens J; Gubareva LV
    Antiviral Res; 2014 Jan; 101():93-6. PubMed ID: 24239666
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro neuraminidase inhibitory concentration (IC
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S; Ishikawa Y; Yamaguchi H; Shiosakai K
    J Infect Chemother; 2018 Sep; 24(9):707-712. PubMed ID: 29759897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
    Ferraris O; Kessler N; Lina B
    Antiviral Res; 2005 Oct; 68(1):43-8. PubMed ID: 16125799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors.
    Escuret V; Frobert E; Bouscambert-Duchamp M; Sabatier M; Grog I; Valette M; Lina B; Morfin F; Ferraris O
    J Clin Virol; 2008 Jan; 41(1):25-8. PubMed ID: 18055253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring.
    Little K; Leang SK; Butler J; Baas C; Harrower B; Mosse J; Barr IG; Hurt AC
    Euro Surveill; 2015; 20(45):. PubMed ID: 26608955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent progress and challenges in the discovery of new neuraminidase inhibitors.
    Chamni S; De-Eknamkul W
    Expert Opin Ther Pat; 2013 Apr; 23(4):409-23. PubMed ID: 23369206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A review of neuraminidase inhibitor susceptibility in influenza strains.
    Spanakis N; Pitiriga V; Gennimata V; Tsakris A
    Expert Rev Anti Infect Ther; 2014 Nov; 12(11):1325-36. PubMed ID: 25301229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A surface plasmon resonance assay for measurement of neuraminidase inhibition, sensitivity of wild-type influenza neuraminidase and its H274Y mutant to the antiviral drugs zanamivir and oseltamivir.
    Somasundaram B; Fee CJ; Fredericks R; Watson AJ; Fairbanks AJ; Hall RJ
    J Mol Recognit; 2015 Sep; 28(9):521-7. PubMed ID: 25727669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influenza viruses with B/Yamagata- and B/Victoria-like neuraminidases are differentially affected by mutations that alter antiviral susceptibility.
    Farrukee R; Leang SK; Butler J; Lee RT; Maurer-Stroh S; Tilmanis D; Sullivan S; Mosse J; Barr IG; Hurt AC
    J Antimicrob Chemother; 2015 Jul; 70(7):2004-12. PubMed ID: 25786478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir.
    Matsuzaki Y; Mizuta K; Aoki Y; Suto A; Abiko C; Sanjoh K; Sugawara K; Takashita E; Itagaki T; Katsushima Y; Ujike M; Obuchi M; Odagiri T; Tashiro M
    Virol J; 2010 Mar; 7():53. PubMed ID: 20202225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accumulation of defective neuraminidase (NA) genes by influenza A viruses in the presence of NA inhibitors as a marker of reduced dependence on NA.
    Nedyalkova MS; Hayden FG; Webster RG; Gubareva LV
    J Infect Dis; 2002 Mar; 185(5):591-8. PubMed ID: 11865415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.
    Nguyen HT; Fry AM; Gubareva LV
    Antivir Ther; 2012; 17(1 Pt B):159-73. PubMed ID: 22311680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa.
    Hurt AC; Ernest J; Deng YM; Iannello P; Besselaar TG; Birch C; Buchy P; Chittaganpitch M; Chiu SC; Dwyer D; Guigon A; Harrower B; Kei IP; Kok T; Lin C; McPhie K; Mohd A; Olveda R; Panayotou T; Rawlinson W; Scott L; Smith D; D'Souza H; Komadina N; Shaw R; Kelso A; Barr IG
    Antiviral Res; 2009 Jul; 83(1):90-3. PubMed ID: 19501261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008-2009 season.
    Baranovich T; Saito R; Suzuki Y; Zaraket H; Dapat C; Caperig-Dapat I; Oguma T; Shabana II; Saito T; Suzuki H;
    J Clin Virol; 2010 Jan; 47(1):23-8. PubMed ID: 19962344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influenza viruses resistant to neuraminidase inhibitors.
    Nitsch-Osuch A; Brydak LB
    Acta Biochim Pol; 2014; 61(3):505-8. PubMed ID: 25195142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs.
    Correia V; Santos LA; Gíria M; Almeida-Santos MM; Rebelo-de-Andrade H
    J Med Virol; 2015 Jan; 87(1):45-56. PubMed ID: 25042157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
    Kawai N; Ikematsu H; Hirotsu N; Maeda T; Kawashima T; Tanaka O; Yamauchi S; Kawamura K; Matsuura S; Nishimura M; Iwaki N; Kashiwagi S
    Clin Infect Dis; 2009 Dec; 49(12):1828-35. PubMed ID: 19911968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds.
    Abed Y; Baz M; Boivin G
    Antivir Ther; 2006; 11(8):971-6. PubMed ID: 17302366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A(H1N1) 2009 pandemic in the Asia-Pacific region, March 2009 to March 2010.
    Hurt AC; Deng YM; Ernest J; Caldwell N; Leang L; Iannello P; Komadina N; Shaw R; Smith D; Dwyer DE; Tramontana AR; Lin RT; Freeman K; Kelso A; Barr IG
    Euro Surveill; 2011 Jan; 16(3):. PubMed ID: 21262183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.